TWI231368B - High energy phototherapeutic agents - Google Patents
High energy phototherapeutic agents Download PDFInfo
- Publication number
- TWI231368B TWI231368B TW088122437A TW88122437A TWI231368B TW I231368 B TWI231368 B TW I231368B TW 088122437 A TW088122437 A TW 088122437A TW 88122437 A TW88122437 A TW 88122437A TW I231368 B TWI231368 B TW I231368B
- Authority
- TW
- Taiwan
- Prior art keywords
- activator
- radiation
- group
- item
- scope
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 33
- 238000003384 imaging method Methods 0.000 claims abstract description 14
- 230000005855 radiation Effects 0.000 claims description 43
- 239000012190 activator Substances 0.000 claims description 32
- 230000004913 activation Effects 0.000 claims description 11
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 10
- -1 aromatic carbohydrates Chemical class 0.000 claims description 7
- 239000002872 contrast media Substances 0.000 claims description 7
- 230000002079 cooperative effect Effects 0.000 claims description 6
- 230000005865 ionizing radiation Effects 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- DBZJJPROPLPMSN-UHFFFAOYSA-N bromoeosin Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C(O)C(Br)=C1OC1=C(Br)C(O)=C(Br)C=C21 DBZJJPROPLPMSN-UHFFFAOYSA-N 0.000 claims description 5
- 229960001483 eosin Drugs 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 150000001409 amidines Chemical class 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 241000258920 Chilopoda Species 0.000 claims description 2
- 150000001298 alcohols Chemical class 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- GVKCHTBDSMQENH-UHFFFAOYSA-L phloxine B Chemical compound [Na+].[Na+].[O-]C(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 GVKCHTBDSMQENH-UHFFFAOYSA-L 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 229910052691 Erbium Inorganic materials 0.000 claims 1
- 241000282326 Felis catus Species 0.000 claims 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 claims 1
- 230000005284 excitation Effects 0.000 claims 1
- 230000026030 halogenation Effects 0.000 claims 1
- 238000005658 halogenation reaction Methods 0.000 claims 1
- 239000011859 microparticle Substances 0.000 claims 1
- 229910052722 tritium Inorganic materials 0.000 claims 1
- 235000021419 vinegar Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 11
- 239000002534 radiation-sensitizing agent Substances 0.000 abstract 2
- 125000001834 xanthenyl group Chemical class C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 41
- 206010028980 Neoplasm Diseases 0.000 description 24
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 9
- 230000007541 cellular toxicity Effects 0.000 description 7
- 229960002143 fluorescein Drugs 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 229910052740 iodine Inorganic materials 0.000 description 6
- 239000011630 iodine Substances 0.000 description 6
- 238000002428 photodynamic therapy Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- VDNLFJGJEQUWRB-UHFFFAOYSA-N rose bengal free acid Chemical compound OC(=O)C1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C(O)=C(I)C=C21 VDNLFJGJEQUWRB-UHFFFAOYSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- QCPFFGGFHNZBEP-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 QCPFFGGFHNZBEP-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000008512 biological response Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000001126 phototherapy Methods 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940020947 fluorescein sodium Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000011287 therapeutic dose Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VFNKZQNIXUFLBC-UHFFFAOYSA-N 2',7'-dichlorofluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(O)C=C1OC1=C2C=C(Cl)C(O)=C1 VFNKZQNIXUFLBC-UHFFFAOYSA-N 0.000 description 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 1
- ZDTNHRWWURISAA-UHFFFAOYSA-N 4',5'-dibromo-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C(Br)=C1OC1=C(Br)C(O)=CC=C21 ZDTNHRWWURISAA-UHFFFAOYSA-N 0.000 description 1
- WLHLYHWMNUCWEV-UHFFFAOYSA-N 4',5'-dichloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C(Cl)=C1OC1=C(Cl)C(O)=CC=C21 WLHLYHWMNUCWEV-UHFFFAOYSA-N 0.000 description 1
- IICCLYANAQEHCI-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5',7'-tetraiodospiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 IICCLYANAQEHCI-UHFFFAOYSA-N 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QVGUJMYYNVCZJR-UHFFFAOYSA-N [Na].[I].[I] Chemical compound [Na].[I].[I] QVGUJMYYNVCZJR-UHFFFAOYSA-N 0.000 description 1
- FBFIOFHXQOSUKD-UHFFFAOYSA-N [Na][Br]I Chemical compound [Na][Br]I FBFIOFHXQOSUKD-UHFFFAOYSA-N 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- XENVCRGQTABGKY-ZHACJKMWSA-N chlorohydrin Chemical compound CC#CC#CC#CC#C\C=C\C(Cl)CO XENVCRGQTABGKY-ZHACJKMWSA-N 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 description 1
- 229960001025 iohexol Drugs 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000001795 light effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- BXBUVIPNRGDTNE-UHFFFAOYSA-N sodium;hydrobromide Chemical compound [Na].Br BXBUVIPNRGDTNE-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009941 weaving Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/819—Multifunctional antigen or antibody
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Radiation-Therapy Devices (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Description
1231368 經濟部智慧財產局員工消費合作社印製 A7 ----------- 五、發明說明(1 ) 發_明之背景 本發明係有關一種高能量光療劑,或更詳細地係有 關輻射激活作用及使用該光療劑或輻射激活劑之治療與 成像方法。更詳細地,係有關罹病組織之治療與成像作 用,该罹病組織諸如腫瘤,特別是癌症腫瘤。 罹病組織或腫瘤,諸如該癌症罹病組織或腫瘤,通常 在稱作輻射治療之一方法中,以離子輻射加以治療。 用於癌症之輻射治療(其一般使用具有丨千電子伏特以 上的能量之電磁輻射),一般藉由以高穿透性離子輻射攻 擊快速生長的細胞而產生作用。因該輻射作用可深入組織 之能力,特別當罹病組織係為骨或其他稠密或不透明的結 構或位於其中時,故其使用頗具吸引力。不幸地,以快速 生長作為致標作用之唯一的標準,並不能將該治療的效應 侷限於癌細胞。 因此,曾改良用以將離子輻射傳送至癌症腫瘤位址之 方法,以將該輻射的效應侷限於癌症腫瘤之一般區域。然 而,因健康組織與癌症組織對於輕射一般具有類似的生物 反應,必須加強所傳送的輪射在該腫瘤内或其附近之效力 (或對其之生物反應),同時不影響周圍的健康組織。 已發展出光動力治療(PDT)作為離子輻射之替代方案 ,其在用於治療多種癌症方面深具希望。光動力治療,係 一種光激活劑與位址專一性輻照(使用非離子化、光輻射) 之組合,以在諸如腫瘤之罹病組織中產生一治療反應。在 光動力治療中,藉由天然方法或經由局部施用,而使得光 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) iL-----------訂--------- (請先閱讀背面之注意事項再填寫本頁) 4 1231368 經濟部智慧財產局員工消費合作社印製
否,係依(1)試劑
本紙張尺度翻t關家標準(CNS)A4娜(21G x 297^^) A7 B7 五、發明說明(2 ) 激活劑之濃度係偏好位於罹病組織之内,而非位於健康的 周圍組織之中。相對於經由標準輻射治療所取得者,此提 供一附加程度的組織專一性,因為光動力治療僅於一光激 活劑存在於組織中時方具有效用。因此,可藉由控制該劑 之分布而避免損傷周圍健康組織。不性地,當於光動力治 療之光照步驟使用傳統方法時,(1)該治療所需的光無法 深入組織,及(2)外科醫師對於治療位址之空間掌控能力 極微。當罹病組織或腫瘤深入地座落於或位於骨或其他不 透明結構中時,其特別麻煩。本發明之部分發明者曾經解 決光動力治療之許多該等問題,如共同讓與之美國專利第 5,829,448號中所示。 具他人則致力於開發藉由上述的離子輻射而 活或活化之試劑。潛在地,該輻射作騎能治療之罹病 織的位置,比光輻射作用可能治療者更加深人。用於該 射作用之試劑係稱作輻射激活劑。亦需要藉由天然方法 經由局部施用,達到輻射激活劑於罹病組織之内的偏好 度,以提供相料㈣鮮輕射治療所轉者之附加的 一性。所需的結果係當輻射激活劑存在於組織中時,輕 作用更具效力’使得僅錄少量的料仙及可治療病 腫瘤或其他罹病組織,及因而降低因附隨的輻射暴露所 成周圍健康組織的潛在損傷。因而,可增強安全性盥效 輻射激活劑方法最終成功或失敗與
i tr--------- (請先閱讀背面之注意事項再填寫本頁) 1231368 ΚΙ 五、發明說明(3 ) 的〜療性能,及(2)在活化位址之疾病專一性而定。然而 目刖所用的試劑與致標之措施,在各項中具有不合格的 結果。 輻射激活劑之治療性能,主要係為相較於未激活組織 而a,所施用輻射劑量在激活組織中之增強的吸收作用之 一函數。該差示吸收作用,一般係藉由使用對於一特定輻 射類型(諸如X光)具有吸收截面的試劑而達成。例如,經 ¥使用以原子形式或納入一分子載劑之金屬或鹵素原子, 因其等具有向的X光截面。該等原子之X光吸收作用,似 乎導致次級輻射釋出、離子化作用及其他化學或物理程序 ,而增加所施用能源之局部細胞毒性(即輻射引發的細胞 死亡’或”光細胞毒性,,)。 然而,高的光細胞毒性並不足以使一試劑成為一個可 被接受的試劑。當未施用能源時,該試劑的效應亦必繹為 極微的(亦即在缺乏輻射作用之下具有低的毒性,或,,暗細 胞毒性”)。不幸地,目前所研究作為輻射激活劑的許多試 wJ具有下列的缺點·(a)相當南的暗細胞毒性,或(b)低 的光細胞毒性-暗細胞毒性之比例,因而限制其等之效力 與可接受度。具有高的光細胞毒性對於暗細胞毒性之比例 的试劑,係為有利的,因其等(1)於一劑量範圍内可安全 使用,(2)在治療位址展現增進的效力(因其等的相對安全 性之故,而能以較高的劑量使用),及(3)將較為病人的身 體所接受。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) illrll4k—— (請先閱讀背面之注意事項再填寫本頁) —訂---------. 經濟部智慧財產局員工消費合作社印製 6 1231368 經濟部智慧財產局員工消費合作社印製 A7 _______B7 _ 五、發明說明(4 ) 目前的許多輻射激活劑之另外的問題在於,該試劑並 未在腫瘤中達成顯著的偏好濃度。更詳細地,大部份的輻 射激活劑之致標作用係基於物理性致標作用,諸如經由滲 漏的神經血管結構而擴散進入腫瘤,其最終的成功或失敗 與否係基於腫瘤對於該試劑之滲透性,其中該試劑為水溶 性或於一懸浮配方物中。結果,一般需要局部或系統投予 高劑量的試劑,以飽和所有的組織,以企望在所需的治療 區域或標的達到一治療濃度。在該試劑之投藥作用後,病 人必須等候數小時至數天之肅清時間,以企望過量的試劑 可自所需治療位址周圍的健康活組織排除。之後,輻照所 需治療位址之殘餘試劑,以企望在罹病組織產生所需的細 胞毒性效應。該方法亦可能因為仍存於周圍健康組織中的 殘餘試劑之不利的但無法避免的活化作用,而不幸地損及 周圍的健康組織。解決該問題之一方法,係將輕射激活劑 與一部份偶合,該部份能改良對於罹病組織之生物致標作 用。然而,已證明該方法很難達成。 若能使用輻射激活劑以增進有關標的尺寸、位址與深 度之辨硪,使能更精確地將治療輕照傳送至標的諸如癌症 腫瘤,亦為非常有利的。合併該試劑的診斷用途(作為一 對比劑)與治療用途(作為一輻射激活劑),將藉由⑴降低 診斷與治療所需程序之數目,⑵降低診斷與治療之總體 時間,及⑶降低成本,而降低病人的風險。 目此,本發明之—目標係開發新的輻射激活劑,其具 10 0 tm (CNS)A4 1 — li-L-----------訂--------- (請先閱讀背面之注音?事項再填寫本頁) 1231368 A7
閱 讀 背 之 注 意 事 項 再 填 本 頁
I 訂
1231368
經濟部智慧財產局員工消費合作社印製 第4圖係鹵素的能量相對於χ光截面之圖。 見重較佳具體例之詳細説明 本發明係有關能有效率地與X光或其他類型的離子輕 射父互作用之試劑,以產生一種有利的生物反應,及係有 關使用該等試劑之治療與成像方法。 本杳明之發明者發現在罹病組織之細胞膜與其他關鍵 組成成份與結構中展現濃度偏好之強輻射劑,諸如後述之 鹵化汕煙,可展現附加的治療劑量增強作用,其優於以已 知試劑或增強機制所可能達到者。該附加的治療劑量增強 作用,係歸因於增進該試劑與罹病組織交互作用時之接近 程度,而在敏感結構輻照與後續的輻射激活期間,增加該 試劑之輕射激活產量之故。更詳細地,大部份的輻射激活 劑之作用方式,係藉由吸收高穿透性能量(其本身與組織 之交互作用極少),然後以穿透性較低、細胞毒性較高的 形式(諸如低能量次級輻射)釋出該能量,其主要僅與鄰近 的生物敏感性構造或物質(諸如細胞膜或基因物質)交互作 本紙張尺度細中國國家標準(CNS)A4規格(210 χ 297公釐)
— — — — — — 4 — — — — ----- (請先閲讀背面之注意事項再填寫本頁) 訂--- 9 1231368
1231368 A7 B7 五、發明說明( 作用而將.亥武劑傳送至該標的),或藉由增加該試劑在 位於、鄰近或進人該標的之局部濃度,例如經由注射、漫 灌或喷灑之局部傳送作用。 較佳,該等試劑具有大的X光截©;高的光細胞毒性 對於暗細胞毒性之比例;蓄積於罹病組織之偏好;低的試 劑成本,自if组織之快速肅清作用;&有效的規程管理 吕己錄(以增進主管單位奐醫學界之接受度)。 本案申请者發現一種符合該標準之試劑類型,其較佳 用於本發明中。戎等試劑係稱作齒化。山煜,及示於第圖 中,其中符號χ、γ與z代表存在於指定位置之各種元素, 而符號R1與R2代表存在於指定位置之各種官能基。代表性 鹵化汕煜之物理與光化學性質(諸如在X、γ與Ζ位置之官 能基R1與R2以及分子量)歸納於所附的第1表。雖然許多鹵 化ΰ山煜係局度溶於水溶液中,一般而言皆展現對於選擇性 分配進入一疏水性環境諸如細胞膜内之偏好。 一般而言’鹵化吡煜之特徵在於低的暗細胞毒性及其 光化學性質貫質上不受局部化學環境或連接於Rl與R2位置 之g此性衍生物之影響。更進一步,鹵化仙煙將基於其固 有的選擇性分配性質而致標一些腫瘤或其他罹病組織之標 的。 鹵煜之一特定實例為四碘四氯螢光素(4,5,6,7_四 氯-2’,4’,5’,7’-四碘螢光素,見第ia圖中之1〇)。更詳細地 ’發現四峨四氣螢光素具有蓄積於一些腫瘤或其他罹病組 本紙張尺度適用中國國家標準(CNS)A4規格(210 χ 297公釐) ill lil· —— (請先閱讀背面之注意事項再填寫本頁) tr· 經濟部智慧財產局員工消費合作社印製 11
經濟部智慧財產局員工消費合作社印製
1231368 織之偏好(即致標作用)。更進一步,四碘四氣螢光素具有 其他的有利特性,諸如其暗細胞毒性極微、成本相當低、 自身體迅速肅清之能力、及已部份建立之規程管理記錄。 更進一步,本案之發明者發現四碘四氣螢光素之特殊化學 性質,使其能以高濃度溶於水溶液中,同時保有對於疏水 性環境諸如細胞膜内之顯著偏好。 本案之發明者亦發現··有關齒化。山煜用以致標特定組 織或其他位址標的之裝置,可藉由在R1與R2位置連接特定 的官能性衍生物,以改變該試劑之化學分配或生物活性, 而加以最佳化。例如,在R1與R2位置連接一或多個致標部 ^以坫進對於諸如癌腫瘤組織或局部感染位址的特定組 織標的之致標能力。該等致標部份包括DNA、RNA、胺基 酸、蛋白質、抗體、配位體、輔抗原、碳水化合物受體或 複合劑、脂質受體或複合劑、蛋白質受體或複合劑、螯合 劑、封裝載劑、短或長鏈脂族或芳族碳水化合物,包括該 等含有酸、酮、醇、g旨、醯胺、胺、腈、疊氮化物或其他 親水性或疏水性部份。 因此,该特性的實例之一係結合四碘四氯螢光素與一 種脂質(經由酯化作用而連接於R1位置),以增加四碘四氯 螢光素之親脂性,及進而改良其於病人中之致標性質。該 種經改良之試劑能以微胞懸浮液方式直接施用,或與諸如 表面活性劑之輸送載劑一起投予,而增加對於腫瘤細胞標 的之致標能力。該試劑之適宜配方物包括局部施用的乳霜 297公釐) 11— -il· --------訂---------^9. (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度_中國國家標準(CNS)A4規格(21? 12 1231368
五、發明說明( 濟 慧 局 員 工 消 與乳液,及用於靜脈注射或非經腸注射之液體。 第4圖顯示,鹵化α山煙之鹵素的強力吸收作用,係發 於遠低於標準的X光診斷或治療設備所用之能量,其一般 高於30千電子伏特。事實上,鹵化,山煜之鹵素含量,使得 此類的試劑成為強力的X光吸收劑,及因而非常適於作為 輻射激活劑。更進一步,因χ光截面係依氟〈氯〈溴〈碘之 -人序而顯著地增加’較佳係於X光激活作用中使用具有高 碘或溴含量的鹵化汕煜。更進一步,試驗顯示:相較於以 其他_素所可能達成者,礙或溴之存在增強激活作用。因 此’如第I表所示,鑑於個別的鹵素含量差異之結果,四 溴四碘螢光素、四碘四氯螢光素、二氫四溴螢光素 B(Phloxine Β)、四碘螢光素Β、及四溴螢光素丫的又光截面 將大於紅色溶劑或四溴螢光素Β,及因此係較佳作為X光 激活劑者。更佳,四碘四氯螢光素及其衍生物之高碘含量 ,以及4,5,6,7-四溴四碘螢光素及其衍生物之附加的溴組 成,使該等試劑成為該類型中之最佳的X光激活劑。 因此,在本發明的一個更佳的具體實例中,係以至少 種鹵化仙煜作為一種又光激活劑或輻射激活劑,以使用 輻射激活作用治療罹病組織。在輕射激活作用之前,該試 劑能以技藝中所熟知之方式而口 [系統(如藉由注射)、 或局又藥。在本發明的另一個更佳的具體實例中,輕射 激活劑係為四碘四氣榮光素或其衍生物或為4,5,6,7-四溴 四碰螢光素或其衍生物。較佳亦使用能量洲千電子伏特 II —— (請先閲讀背面之注意事項再填寫本頁) n ϋ n 訂 · 本紙張尺财國賴 13
I 111231368 A7 五、發明說明( 經 濟 部 智 慧 財 產 局 員 工 消 費 合 作 社 印 製 及β〇〇〇百萬電子伏特之X光或其他離子輻射,以活化該 試劑。較佳,該試劑係以能量超過3〇千電子伏特之X光加 以活化。 本案之申請者亦發現_化ϋ山煜可作為X光或其他離子 輻射成像作用之成像對比劑,諸如CAT掃瞄、螢光圖像攝 影或其他相關程序。更詳細地,本案發明者發現鹵化仙煜 特別適於作為成像對比齊卜因#等之大的χ光截面及因其 等之化學結構,其化學結構因為顯著的_素含量而具有高 電子密度,使其對於成像作用所用的χ光或其他離子輻射 呈現不透明。例如,對於CAT掃目苗或一般χ光成像所用之 X光,四碘四氣螢光素係高度不透明的。第2與3圖顯示, 四碘四氣螢光素相對於標準X光對比劑與一對照組之不透 明度。該等圖係本發明之發明者所進行實驗的實際情形之 圖式例如,第2圖所示含有各種溶液的試管之CA丁掃瞄 影像顯示,碘(35〇毫克碘/毫升含水基質)、四碘四氯螢 素(225毫克碘_素/毫升鹽水)、〇mnipaqueTM(35〇毫克碘/ 升Iohexol)具有類似的χ光密度。更進一步,該等密度顯。 地大於對照組(鹽水)之密度。第3圖之圖式中所示該等相 同/合液的不同稀釋液(置於96孔試樣皿之孔中)之丁掃瞄 影像,進一步顯示四碘四氯螢光素在一個濃度範圍内具有 與標準X光對比劑可相比的反應。 因此,在本發明的另一個較佳具體例中,係使用至 一種齒化汕煜作為以χ光或離子輻射為主的成像作用之 光毫著 少
—I —- J l·—--------訂--------- (請先閱讀背面之注意事項再填寫本頁) 12 1231368 五、發明說明( 成像對比劑’及偵測罹病組織,然後以該組織中之殘餘試 劑的輻射激活作用而治療所谓測到的罹病組織。 激活劑 D亥敘述僅供說明之用,而非限制本申請案之發明,本 發明係由下列之中請專利範圍所界定。例如,習知技藝者 將瞭解此述用於“㈣特騎狀致標仙,可適用於 或在其他情況下施用於其他強輻射物質,包括傳統的輻射 需要受到文字 在所附之申請專利範圍中,列出新的與 專利保護之申請專利範圍。 經濟部智慧財產局員工消費合作社印製
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 15 1231368 A7 B7 五、發明說明(13 ) 第I表.鹵化汕煜實例之物理性質 化合物 取代 分子量(克) X Y Z R1 R2 螢光素 氫 氫 氫 納 鈉 376 4’,5’-二氯螢光素 氯 氫 氫 納 納 445 2’,7’-二氯螢光素 氫 氯 氫 鈉 鈉 445 4,5,6,7-四氯螢光素 氫 氫 氯 氫 氫 470 2’,4’,5’,7’-四氯螢光素 氣 氯 氫 鈉 鈉 514 二溴螢光素 溴 氫 氫 鈉 鈉 534 紅色溶劑72 氫 臭 氫 氫 氫 490 二碘螢光素 破 氫 氫 納 鈉 628 四溴螢光素B n〇2 溴 氫 鈉 納 624 四溴螢光素Y 溴 溴 氫 納 納 692 乙基四溴螢光素 溴 溴 氫 c2H5 鉀 714 四蛾螢光素B 碘 碘 氫 納 納 880 二氫四溴螢光素B 溴 溴 氯 納 鈉 830 四蛾四氣螢光素 碘 碘 氣 納 鈉 1018 4,5,6,7-四溴四碳螢光素 碘 碘 溴 鈉 鈉 1195 ------- I U--- I-------訂--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 16
Claims (1)
- BS C3 DS 經濟部智慧財產局員工消費合作社印製 六、申請專利範圍 第88122437號專利再審查案申請專利範圍修正本 修正日期:93年12月 L —種利用㈣激活作用或離子輻射來治療罹病組織 之幸田射激活劑’其包含一種鹵化„山埕㈣她咖卜 2.如申請專利範圍第旧之輻射激活劑,其中該齒化。山 煜係選自於由四碘四氣螢光素{R〇Se 及其官 能性衍生物所構成之群中。 3 .如申請專利範圍第i項之㈣激活劑,其中該齒化仙 埕係選自於由4,5,6,7-四溴四峡螢光素及其官能性衍 生物所構成之群中。 4·如申請專利範圍第!項之輻射激活劑,其中該鹵化汕 煜係選自於由二氫四溴螢光素B(Phl〇xine B)、四碘 螢光素B(Erythr0Sin B)、四溴螢光素Y(E〇sin γ)及其 等之官能性衍生物所構成的群中。 5·如申凊專利範圍第丄項之輻射激活劑,其中該鹵化。山 煜包括-致標部份作為_冑能性射物,該致標部 份係選自於由DNA、RNA、胺基酸、蛋白質、抗體 配位體、輔抗原.、碳水化合物受體或複合劑、脂 質党體或複合劑、蛋白質受體或複合劑、螯合劑、 封破載劑 '短或長鏈脂族或芳族碳水化合物、醛、 _、醇、醋、醯胺1、腈、疊氮化物及其他親水 性或疏水性部份所構成之群中。 6.如申請專利範圍第!項之輪射激活劑,其中該輻射激 (請先閲讀背面之注意事 填寫本頁)· -絲 本紙張尺度適周中國固家-- 1231368 B3 C3 DS 申5月專利範圍 活劑亦為一種成像對比劑。 、申明專利乾圍第6項之輕射激活劑,其中該輕射激 d係用作為-種供χ光成像作用之用的 劑。 8.如申請專利範圍第6項之轄射激活劑,其中該幸昌射激 活劑係用作為一種供CAT掃猫之用的成像對比劑。 9·如申5月專利範圍第1項之輕射激活劑,其中該鹵化口山 煜具有高含量之—種元素,該元素係選自於由蛾與 溴所構成之群中。 如申4專利範圍第丨項之㈣激活劑,其中該函化。山 煜係利用具有一高於3〇千電子伏特之能量的X光予 以活化。 士申。月專利犯圍第i項之輕射激活劑,其中該試劑係 囊=於-輸送載劑中,該輸送載劑係選自於由微胞 、耄微顆粒及脂質體所構成之群中。 (請先閱讀背面之注意事寫本頁) !λμ. 寫本 訂· •銘 經濟部智慧財產局員工消費合作社印製 本紙張尺度適 規格(2j〇 >: 297 4-S-
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/216,787 US6331286B1 (en) | 1998-12-21 | 1998-12-21 | Methods for high energy phototherapeutics |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI231368B true TWI231368B (en) | 2005-04-21 |
Family
ID=22808515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW088122437A TWI231368B (en) | 1998-12-21 | 1999-12-20 | High energy phototherapeutic agents |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US6331286B1 (zh) |
| EP (1) | EP1192450B1 (zh) |
| JP (1) | JP3735770B2 (zh) |
| KR (1) | KR20010089658A (zh) |
| CN (1) | CN1331797A (zh) |
| AR (1) | AR021967A1 (zh) |
| AU (1) | AU2368700A (zh) |
| BR (1) | BR9916398A (zh) |
| CA (1) | CA2352094C (zh) |
| ES (1) | ES2526460T3 (zh) |
| HK (1) | HK1041726A1 (zh) |
| IL (1) | IL143468A0 (zh) |
| TW (1) | TWI231368B (zh) |
| WO (1) | WO2000037927A1 (zh) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331286B1 (en) * | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
| US6493570B1 (en) | 1998-11-02 | 2002-12-10 | Photogen, Inc. | Method for improved imaging and photodynamic therapy |
| US7390668B2 (en) * | 1996-10-30 | 2008-06-24 | Provectus Pharmatech, Inc. | Intracorporeal medicaments for photodynamic treatment of disease |
| US7036516B1 (en) | 1996-10-30 | 2006-05-02 | Xantech Pharmaceuticals, Inc. | Treatment of pigmented tissues using optical energy |
| US20060095097A1 (en) * | 1996-10-30 | 2006-05-04 | Provectus Devicetech, Inc. | Treatment of pigmented tissue using optical energy |
| US8974363B2 (en) | 1997-12-11 | 2015-03-10 | Provectus Pharmatech, Inc. | Topical medicaments and methods for photodynamic treatment of disease |
| US8557298B2 (en) | 1998-08-06 | 2013-10-15 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
| US7648695B2 (en) * | 1998-08-06 | 2010-01-19 | Provectus Pharmatech, Inc. | Medicaments for chemotherapeutic treatment of disease |
| US6986740B2 (en) * | 1998-11-02 | 2006-01-17 | Xantech Pharmaceuticals, Inc. | Ultrasound contrast using halogenated xanthenes |
| US7384623B1 (en) | 1998-12-21 | 2008-06-10 | Provectus Pharmatech, Inc. | High energy phototherapeutic agents |
| US20020001567A1 (en) * | 1998-12-21 | 2002-01-03 | Photogen, Inc. | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| US8470296B2 (en) * | 1998-12-21 | 2013-06-25 | Provectus Pharmatech, Inc. | Intracorporeal medicaments for high energy phototherapeutic treatment of disease |
| AR022404A1 (es) * | 1999-01-25 | 2002-09-04 | Photogen Inc | Metodo y agentes para la terapia de radiacion mejorada |
| ATE406157T1 (de) * | 1999-08-13 | 2008-09-15 | Provectus Pharmatech Inc | Verbesserte topische medikamente sowie verfahren zur photodynamischer behandlung von krankheiten |
| GB0017084D0 (en) * | 2000-07-13 | 2000-08-30 | Univ Bristol | Inhibition of the cystic fibrosis transmembrane conductance regulator chloride channel |
| WO2002023391A1 (en) * | 2000-09-14 | 2002-03-21 | Koninklijke Philips Electronics N.V. | Method of and system for storing a data item |
| US20020107281A1 (en) * | 2000-09-22 | 2002-08-08 | Photogen, Inc. | Phototherapeutic and chemotherapeutic immunotherapy against tumors |
| US6500630B2 (en) * | 2001-01-12 | 2002-12-31 | Mayo Foundation For Medical Education And Research | Marker for inflammatory conditions |
| EP1490053B1 (en) * | 2002-04-02 | 2008-01-09 | NERVIANO MEDICAL SCIENCES S.r.l. | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy |
| US7981928B2 (en) * | 2002-09-05 | 2011-07-19 | Nanodynamics, Inc. | Chemotherapy method using x-rays |
| US20050053895A1 (en) | 2003-09-09 | 2005-03-10 | The Procter & Gamble Company Attention: Chief Patent Counsel | Illuminated electric toothbrushes emitting high luminous intensity toothbrush |
| KR101125678B1 (ko) | 2004-02-06 | 2012-03-28 | 롬 앤드 하스 일렉트로닉 머트어리얼즈, 엘.엘.씨. | 개선된 이미지화 조성물 및 방법 |
| US20050175941A1 (en) | 2004-02-06 | 2005-08-11 | Rohm And Hass Electronic Materials, L.L.C. | Imaging composition and method |
| US7977026B2 (en) | 2004-02-06 | 2011-07-12 | Rohm And Haas Electronic Materials Llc | Imaging methods |
| US7144676B2 (en) | 2004-02-06 | 2006-12-05 | Rohm And Haas Electronic Materials Llc | Imaging compositions and methods |
| JP2008502717A (ja) * | 2004-06-10 | 2008-01-31 | ザンテック ファーマスーティカルズ,インク. | 放射性標識ハロゲン化キサンテンを使用する陽電子放出イメージング用の診断薬および放射性標識ハロゲン化キサンテン診断薬による陽電子放出イメージング方法 |
| RU2270045C1 (ru) * | 2004-06-24 | 2006-02-20 | Федеральное государственное унитарное предприятие Государственный научный центр - Институт биофизики Федерального медико-биологического агентства (ГНЦ-ИБФ) | Способ фотон-захватной терапии опухолей |
| WO2006037081A2 (en) * | 2004-09-28 | 2006-04-06 | The Regents Of The University Of California | Nanoparticle radiosensitizers |
| KR100651728B1 (ko) * | 2004-11-10 | 2006-12-06 | 한국전자통신연구원 | 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법 |
| EP1825560A4 (en) * | 2004-11-20 | 2010-09-15 | Kenneth E Salsman | DEVICE FOR EMISSION OF HIGH FREQUENCY SIGNALS |
| US7280078B2 (en) | 2004-11-20 | 2007-10-09 | Scenterra, Inc. | Sensor for detecting high frequency signals |
| US8109981B2 (en) | 2005-01-25 | 2012-02-07 | Valam Corporation | Optical therapies and devices |
| US20080269065A1 (en) * | 2007-04-30 | 2008-10-30 | Syntrix Biosystems, Inc. | Conformationally Constrained Analytical Probes |
| US20090104212A1 (en) * | 2007-08-06 | 2009-04-23 | Immunolight | Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption |
| US9273022B2 (en) | 2009-09-18 | 2016-03-01 | Provectus Pharmaceuticals, Inc. | Process for the synthesis of 4,5,6,7-tetrachloro-3′,6′-dihydroxy-2′, 4′, 5′7′-tetraiodo-3H-spiro[isobenzofuran-1,9′-xanthen]-3-one (Rose Bengal) and related xanthenes |
| KR101494055B1 (ko) * | 2009-09-18 | 2015-02-16 | 프로벡투스 파마슈티컬스 인코포레이티드 | 4,5,6,7-테트라클로로-3'',6''-다이하이드록시-2'',4'',5'',7''- 테트라요오도-3h-스피로[이소벤조푸란-1,9''-잔텐]-3-온(로즈 벤갈) 및 관련 잔텐의 합성 방법 |
| US9642687B2 (en) | 2010-06-15 | 2017-05-09 | The Procter & Gamble Company | Methods for whitening teeth |
| RU2533267C1 (ru) * | 2013-10-07 | 2014-11-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ТГМУ Минздрава России) | Способ фотон-захватной терапии опухолей |
| US11426379B2 (en) | 2017-11-29 | 2022-08-30 | Provectus Pharmatech, Inc. | Combination of local and systemic therapies for enhanced treatment of dermatologic conditions |
| CN112996502B (zh) | 2018-05-16 | 2023-10-31 | 普罗维克图斯药品技术公司 | 卤代呫吨针对难治性小儿实体瘤的体外和异种移植抗肿瘤活性 |
| CN111317731A (zh) * | 2018-12-17 | 2020-06-23 | 中山大学 | 9-(2-羧基苯基)呫吨类化合物制备fto抑制剂及其治疗作用 |
| US20200222564A1 (en) * | 2019-01-15 | 2020-07-16 | Tianjin University | Compound Amphiphilic Peptide Nanomicelle, Preparation and Use Thereof |
| US12064507B2 (en) | 2019-11-19 | 2024-08-20 | Provectus Pharmatech, Inc. | Composition and method for oral treatment of leukemia |
| US11419844B2 (en) | 2019-11-19 | 2022-08-23 | Provectus Pharmatech, Inc. | Halogenated xanthene composition and method for treating hematologic cancers |
| CA3172124A1 (en) | 2020-03-26 | 2021-09-30 | Aru NARENDRAN | Uses of halogenated xanthenes in oncology and virology |
| US11938182B2 (en) | 2020-03-26 | 2024-03-26 | Provectus Pharmatech, Inc. | Halogenated xanthenes as vaccine adjuvants |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3868950A (en) | 1970-09-24 | 1975-03-04 | Yoshio Kato | Body treating apparatus |
| US4066650A (en) | 1971-02-11 | 1978-01-03 | Egyud Laszlo G | Keto-aldehyde-amine addition products and method of making same |
| US3986513A (en) | 1976-01-29 | 1976-10-19 | Joseph Lester Stuhl | Apparatus for irradiating the skin |
| IE47132B1 (en) | 1977-08-19 | 1983-12-28 | Roche Products Ltd | Novel nitroimidazoles and pharmaceutical preparations containing these as well as their manufacture |
| US4172979A (en) | 1978-06-15 | 1979-10-30 | Morrison Richard A | Method and apparatus for automatically providing radiation therapy treatment conforming to a desired volume of tissue |
| US4282232A (en) | 1979-04-26 | 1981-08-04 | Research Corporation | Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof |
| US4371540A (en) | 1979-09-14 | 1983-02-01 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroimidazoles of low toxicity and high activity as radiosensitizers of hypoxic tumor cells |
| US4444189A (en) | 1981-12-21 | 1984-04-24 | Seiverd Paul J | Phototherapy booth |
| US4462992A (en) | 1982-02-08 | 1984-07-31 | Research Corporation | Nitroimidazole radiosensitizers for hypoxic tumor cells and compositions thereof |
| US4490543A (en) * | 1982-11-12 | 1984-12-25 | University Of Northern Iowa Foundation | Low toxicity radiation sensitizer |
| US4691332A (en) | 1983-03-14 | 1987-09-01 | American Science And Engineering, Inc. | High energy computed tomography |
| US4599227A (en) | 1983-11-07 | 1986-07-08 | Wisconsin Alumni Research Foundation | Injectable pharmaceutical preparation for the induction of multiple follicular growth |
| US4681091A (en) | 1984-08-03 | 1987-07-21 | Picker Donald H | Combination modality cancer therapy |
| US4789501A (en) | 1984-11-19 | 1988-12-06 | The Curators Of The University Of Missouri | Glass microspheres |
| US5215738A (en) | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
| HU195487B (en) | 1985-06-04 | 1988-05-30 | Egyt Gyogyszervegyeszeti Gyar | Process for producing quinoline derivatives |
| FR2596989B1 (fr) | 1986-04-14 | 1990-05-18 | Air Liquide | Produit de radiosensibilisation des tissus biologiques en radiotherapie |
| US5616584A (en) | 1986-09-25 | 1997-04-01 | Sri International | 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents |
| US5175287A (en) | 1986-09-25 | 1992-12-29 | S R I International | Process for preparing 1,2,4-benzotriazine oxides |
| US5019368A (en) | 1989-02-23 | 1991-05-28 | Cancer Biologics, Inc. | Detection of necrotic malignant tissue and associated therapy |
| US5026694A (en) | 1987-04-13 | 1991-06-25 | The British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
| US4921963A (en) | 1987-04-13 | 1990-05-01 | British Columbia Cancer Foundation | Platinum complexes with one radiosensitizing ligand |
| CA1329206C (en) | 1987-06-10 | 1994-05-03 | Tsutomu Kagiya | Fluorine-containing nitroazole derivatives and radiosensitizer comprising the same |
| US5304654A (en) | 1987-06-10 | 1994-04-19 | Yasunori Nishijima | Fluorine-containing nitroimidazole compounds |
| US4856528A (en) | 1987-06-26 | 1989-08-15 | John Hopkins University | Tumor volume determination |
| US4957481A (en) | 1987-10-01 | 1990-09-18 | U.S. Bioscience | Photodynamic therapeutic technique |
| JPH0819111B2 (ja) | 1987-10-22 | 1996-02-28 | ポーラ化成工業株式会社 | 2―ニトロイミダゾール誘導体及びこれを有効成分とする放射線増感剤 |
| US5053006A (en) | 1988-04-19 | 1991-10-01 | Watson Brant D | Method for the permanent occlusion of arteries |
| US4897423A (en) | 1988-08-02 | 1990-01-30 | Merck & Co. Inc. | Dinitrobenzenesulfonamides |
| US4880821A (en) | 1988-08-17 | 1989-11-14 | Merck & Co., Inc. | α-nitroalkylnitrobenzenesulfonamides |
| US5036089A (en) | 1988-11-25 | 1991-07-30 | Warner-Lambert Company | 2-oxazolidinone derivatives of nitroimidazoles and pharmaceutical compositions useful as sensitizing agents |
| US4954515A (en) | 1988-11-25 | 1990-09-04 | Warner-Lambert Company | Haloalkylaminomethyl-2-nitro-1H-imidazoles |
| US5036096A (en) | 1988-11-25 | 1991-07-30 | Warner-Lambert Company | Aziridino derivatives of nitroimidazoles and pharmaceutical compositions of selected derivatives |
| IL92597A0 (en) | 1988-12-14 | 1990-08-31 | Yasunori Nishijima President K | Novel fluorine-containing 2-nitroimidazole derivatives and radiosensitizer comprising the same |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
| US5641764A (en) | 1989-03-31 | 1997-06-24 | Peter Maccallum Institute | Halogenated DNA ligand radiosensitizers for cancer therapy |
| US5008907A (en) | 1989-05-31 | 1991-04-16 | The Regents Of The University Of California | Therapy x-ray scanner |
| US4973848A (en) | 1989-07-28 | 1990-11-27 | J. Mccaughan | Laser apparatus for concurrent analysis and treatment |
| US5733572A (en) | 1989-12-22 | 1998-03-31 | Imarx Pharmaceutical Corp. | Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles |
| KR927003539A (ko) | 1990-01-26 | 1992-12-18 | 스즈끼 쯔네시 | 2-니트로 이미다졸 유도체, 그의 제조방법 및 이를 유효성분으로 하는 방사선 증감제 |
| US5147652A (en) | 1990-07-03 | 1992-09-15 | Cell Research Corporation | Autobiotics and their use in eliminating nonself cells in vivo |
| US5282781A (en) | 1990-10-25 | 1994-02-01 | Omnitron International Inc. | Source wire for localized radiation treatment of tumors |
| US5149801A (en) | 1990-11-21 | 1992-09-22 | The Regents Of The University Of California | Boronated porphyrin compounds |
| US5654423A (en) | 1990-11-21 | 1997-08-05 | Regents Of The University Of California | Boronated metalloporphyrine and therapeutic methods |
| US5294715A (en) | 1991-02-01 | 1994-03-15 | University Of Pittsburgh | Acridine-intercalator based hypoxia selective cytotoxins |
| US5128139A (en) | 1991-02-15 | 1992-07-07 | Nu Skin International, Inc. | Composition containing liposome-entrapped grapefruit seed extract and method for making |
| US5225182A (en) | 1991-10-31 | 1993-07-06 | Sharma Yash P | Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system |
| MX9304399A (es) | 1992-07-31 | 1994-02-28 | Warner Lambert Co | Proceso novedoso para preparar [[2-bromoetil)-amino]metil]-2-nitro-1h-imidazol-1-etanol quiral y compuestos relacionados. |
| ATE219688T1 (de) | 1994-03-28 | 2002-07-15 | Nycomed Imaging As | Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel |
| US5502094A (en) | 1994-05-20 | 1996-03-26 | Minnesota Mining And Manufacturing Company | Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use |
| US5556992A (en) * | 1994-09-02 | 1996-09-17 | Universite De Montreal | Novel rhodamine derivatives for photodynamic therapy of cancer and in vitro purging of the leukemias |
| US5935942A (en) * | 1994-12-14 | 1999-08-10 | Zeimer; Ran | Selective and non-invasive visualization or treatment of vasculature |
| US5602142A (en) | 1994-12-21 | 1997-02-11 | Evanston Hospital Corporation | DNA-affinic hypoxia selective cytotoxins |
| US5576013A (en) | 1995-03-21 | 1996-11-19 | Eastern Virginia Medical School | Treating vascular and neoplastic tissues |
| US5700825A (en) | 1995-03-31 | 1997-12-23 | Florida State University | Radiosensitizing diamines and their pharmaceutical preparations |
| US5780052A (en) | 1995-04-24 | 1998-07-14 | Northeastern University | Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
| US5756726A (en) | 1995-06-02 | 1998-05-26 | Pharmacyclics, Inc. | Methods of producing singlet oxygen using compounds having improved functionalization |
| US5780653A (en) | 1995-06-07 | 1998-07-14 | Vivorx Pharmaceuticals, Inc. | Nitrophenyl, 10-deacetylated substituted taxol derivatives as dual functional cytotoxic/radiosensitizers |
| IT1275571B (it) * | 1995-07-19 | 1997-08-07 | Consiglio Nazionale Ricerche | Substrati fluorogenici suscettibili di fotoattivazione previa trasformazione per via enzimatica atti alla diagnosi ed alla terapia fotodinamica dei tumori |
| US5829448A (en) | 1996-10-30 | 1998-11-03 | Photogen, Inc. | Method for improved selectivity in photo-activation of molecular agents |
| US6331286B1 (en) * | 1998-12-21 | 2001-12-18 | Photogen, Inc. | Methods for high energy phototherapeutics |
| US5832931A (en) | 1996-10-30 | 1998-11-10 | Photogen, Inc. | Method for improved selectivity in photo-activation and detection of molecular diagnostic agents |
| US5827186A (en) | 1997-04-11 | 1998-10-27 | Light Sciences Limited Partnership | Method and PDT probe for minimizing CT and MRI image artifacts |
| JP2003520192A (ja) | 1998-10-29 | 2003-07-02 | ザ ゼネラル ホスピタル コーポレーション | 強化された放射線治療 |
-
1998
- 1998-12-21 US US09/216,787 patent/US6331286B1/en not_active Expired - Lifetime
-
1999
- 1999-12-16 KR KR1020017007788A patent/KR20010089658A/ko not_active Withdrawn
- 1999-12-16 BR BR9916398-5A patent/BR9916398A/pt not_active IP Right Cessation
- 1999-12-16 HK HK02103333.8A patent/HK1041726A1/zh unknown
- 1999-12-16 CA CA2352094A patent/CA2352094C/en not_active Expired - Lifetime
- 1999-12-16 JP JP2000589937A patent/JP3735770B2/ja not_active Expired - Fee Related
- 1999-12-16 CN CN99814880A patent/CN1331797A/zh active Pending
- 1999-12-16 ES ES99967402.1T patent/ES2526460T3/es not_active Expired - Lifetime
- 1999-12-16 AU AU23687/00A patent/AU2368700A/en not_active Abandoned
- 1999-12-16 WO PCT/US1999/030156 patent/WO2000037927A1/en not_active Ceased
- 1999-12-16 EP EP99967402.1A patent/EP1192450B1/en not_active Expired - Lifetime
- 1999-12-16 IL IL14346899A patent/IL143468A0/xx unknown
- 1999-12-20 TW TW088122437A patent/TWI231368B/zh not_active IP Right Cessation
- 1999-12-21 AR ARP990106641A patent/AR021967A1/es unknown
-
2005
- 2005-05-09 US US11/124,654 patent/US20050207976A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2368700A (en) | 2000-07-12 |
| AR021967A1 (es) | 2002-09-04 |
| JP2002533355A (ja) | 2002-10-08 |
| CA2352094C (en) | 2010-12-07 |
| EP1192450B1 (en) | 2014-12-03 |
| EP1192450A1 (en) | 2002-04-03 |
| WO2000037927A1 (en) | 2000-06-29 |
| US6331286B1 (en) | 2001-12-18 |
| HK1041726A1 (zh) | 2002-07-19 |
| KR20010089658A (ko) | 2001-10-08 |
| BR9916398A (pt) | 2001-09-11 |
| JP3735770B2 (ja) | 2006-01-18 |
| CA2352094A1 (en) | 2000-06-29 |
| ES2526460T3 (es) | 2015-01-12 |
| IL143468A0 (en) | 2002-04-21 |
| US20050207976A1 (en) | 2005-09-22 |
| EP1192450A4 (en) | 2003-05-21 |
| CN1331797A (zh) | 2002-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI231368B (en) | High energy phototherapeutic agents | |
| CN100382846C (zh) | 用于改进成像及光动力治疗的方法 | |
| Kamkaew et al. | Scintillating nanoparticles as energy mediators for enhanced photodynamic therapy | |
| Ingrand | Characteristics of radio-isotopes for intra-articular therapy | |
| US20070274909A1 (en) | Radiation Therapy and Medical Imaging Using Uv Emitting Nanoparticles | |
| US20130195979A1 (en) | Core-Excited Nanoparticles and Methods of Their Use in the Diagnosis and Treatment of Disease | |
| US20090101841A1 (en) | Ionizing-radiation-responsive compositions, methods, and systems | |
| US20090104179A1 (en) | Ionizing-radiation-responsive compositions, methods, and systems | |
| TW200914054A (en) | Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption | |
| JP2002535291A (ja) | 改善された放射線治療のための方法 | |
| US20170224821A1 (en) | Ionizing-radiation-responsive compositions, methods, and systems | |
| Torrisi et al. | Study of gold nanoparticles for mammography diagnostic and radiotherapy improvements | |
| CN107213479B (zh) | 一种包含过氧化氢酶的组合物及用途 | |
| US7384623B1 (en) | High energy phototherapeutic agents | |
| CZ401898A3 (cs) | Nové radiofarmaceutické přípravky a matrice a jejich použití | |
| US20090104113A1 (en) | Ionizing-radiation-responsive compositions, methods, and systems | |
| GB2453860A (en) | Ionising-radiation sensitive composition comprising luminescent and photosensitive materials | |
| US20090101840A1 (en) | Ionizing-radiation-responsive compositions, methods, and systems | |
| RU2270045C1 (ru) | Способ фотон-захватной терапии опухолей | |
| RU2781902C1 (ru) | Способ лечения аденокарциномы эрлиха методом лучевой терапии | |
| MXPA01006368A (en) | High energy phototherapeutic agents | |
| Kiran et al. | X-ray Triggered Photodynamic Therapy | |
| 이우승 | Development of Radioluminescent Liposomal Nanoplatform for Radioisotope Induced Photodynamic Therapy | |
| グリオーマの放射線治療に向けての et al. | Gold nano-particles as radiosensitizers for glioma radiotherapy | |
| MXPA01007487A (es) | Metodo para terapia de radiacion mejorada |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |